ZERBAXA (Ceftolozane/Tazobactam) Review

December 20, 2014

ZERBAXA, otherwise known as Ceftolozane/Tazobacktum deals with serious urinary tract infections that are resistant to other forms of treatment. This new antibiotic is now approved in the U.S. for treatment of Gram-negative bacteria.

The U.S. Food and Drug Administration has recently approved ZERBAXA for treating adults with urinary tract infections (UTI) and intra-abdominal infections (IAI) that are more complicated than your run-of-the mill infection. It’s use is for treating UTI’s caused by designated susceptible Gram-negative bacteria.

ZERBAXA (Ceftolozane/Tazobactam) Review

where-to-buy-ZERBAXA-CeftolozaneTazobactamThis new drug seems very promising for people suffering from chronic and complicated urinary tract infections. The pharmacutical company, Cubist, states the this new treatment for UTI will help “arm physicians in the battle against gram negative bacteria, where few treatment options exist.” ZEBAXA (Ceftolozane/Tazobacktum) is just one new drug that could potentially help us deal with this very serious threat to our health. In clinical trials, both UTI and IAI sufferers were successfully treated with Ceftolozane/Tazobactam.

Unfamiliar with gram negative bacteria? The CDC has classified these as some of the most serious threats to the public’s health. This type of bacteria is responsible for a majority of the urinary tract infections and intra-abdominal infections throughout the United States.

ZERBAXA (Ceftolozane/Tazobactam) Side Effects

urinary-tract-infection-treatmentsPlease consult your medical practitioner before taking any treatment for UTI or IAI. The most common side effects associated with ZERBAXA (Ceftolozane/Tazobactam) are nausea, diarrhea, headache and pyrexia. Please visit the official homepage of the medication for more information.

ZERBAXA (Ceftolozane/Tazobactam) Outlook for Treatment of UTI and IAI

According to Louis B. Rice, M.D., Joukowsky Family Professor of Medicine and Chairman of the Department of Medicine at Warren Alpert Medical School of Brown University, ZERBAXA (Ceftolozane/Tazobactam) is a “novel treatment” for gram negative pathogens that cause UTI and IAI. These bacteria are becoming increasingly resistant to existing medical treatment and pose a serious threat to public health.

The GAIN Act provides incentives for the medical community to develop medications that treat serious or life-threatening conditions caused by drug resistant bacteria. ZERBAXA (Ceftolozane/Tazobactam) is the first new medication approved under this act and has gone through full FDA approval.

The pharmaceutical company responsible for this treatment of UTI and IAI, Cubist, has stated that their goal is to develop ten brand new antibiotics by the end of 2020.

ZERBAXA (Ceftolozane/Tazobactam)

Ask your medical practitioner for more information on where to buy ZERBAXA (Ceftolozane/Tazobactam) or if your causes of UTI or IAI call for this type of treatment. Until the medication is officially released for prescription, there are a lot of other options out there. For instance, Flotrol is a great natural method to relieve symptoms and treat UTI.

To take steps to maintain your bladder and urinary tract health, try a natural method. This is especially useful for those who have symptoms that seem to come and go. There’s been a lot of success with this type of treatment, but for extreme cases, you will might need a prescription. For the best over the counter solution, check out Flotrol below.

ZERBAXA-Ceftolozane-Tazobactam

treatment-for-uti

Summary
Review Date
Reviewed Item
ZERBAXA (Ceftolozane/Tazobactam)
Author Rating
5

Comments are closed.

  • Inc-Reviews.com is operated and maintained by Patrick Boneville in Miami, FL. Unlike some of those other review sites, we pride ourselves on giving accurate information and back up our reviews, testimonials, and guides with original sources. See our sources page here.
Patrick Boneville | Copyright © 2012-2013 Inc Reviews. Designed by .